Biosyent Inc. (CVE:RX) insider Alfred D’souza sold 2,100 shares of Biosyent stock in a transaction that occurred on Wednesday, June 6th. The stock was sold at an average price of C$10.05, for a total value of C$21,105.00.
Alfred D’souza also recently made the following trade(s):
- On Friday, June 8th, Alfred D’souza sold 2,000 shares of Biosyent stock. The stock was sold at an average price of C$10.03, for a total value of C$20,060.00.
Shares of RX traded down C$0.05 on Thursday, reaching C$9.80. 3,211 shares of the stock traded hands, compared to its average volume of 7,777. Biosyent Inc. has a 12 month low of C$7.85 and a 12 month high of C$11.00.
Biosyent (CVE:RX) last released its quarterly earnings data on Wednesday, March 21st. The company reported C$0.10 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of C$0.10. The business had revenue of C$5.90 million for the quarter. Biosyent had a return on equity of 25.90% and a net margin of 23.96%.
A number of analysts have recently issued reports on RX shares. Bloom Burton restated an “accumulate” rating on shares of Biosyent in a research report on Thursday, March 22nd. Raymond James set a C$12.50 price objective on Biosyent and gave the company an “outperform” rating in a research report on Tuesday, May 1st.
Biosyent Company Profile
BioSyent Inc, a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository designed to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of non-muscle invasive papillary bladder cancer.
Receive News & Ratings for Biosyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent and related companies with MarketBeat.com's FREE daily email newsletter.